The UC Davis Cancer Center, an integrated program with Lawrence Livermore National Labs (LLNL), is a matrix organization under the aegis of the UC Davis Health System (combining the UC Davis School of Medicine and the UC Davis Medical Center), and the University of California, Davis. Located on the campus of the UC Davis Medical Center in Sacramento, California, the cancer center's administrative, clinical and research facilities are under the leadership of the Principal Investigator of this P30 competitive renewal;an initial P30 was awarded to the Cancer Center on July 1, 2002. The Cancer Center draws its 186 members from the faculty of UC Davis and investigators at the LLNL, the USDA Western Human Nutrition Research Center and the California Department of Public Health. Peer-reviewed funding for UC Davis Cancer Center members totals $81,918,736.00 of which $21,771,164.00 (direct costs) is provided by the NCI. Investigators at the other organizations contributing membership are also provided research funding through the US Department of Energy, the US Department of Agriculture, and the State of California respectively. At the UC Davis Cancer Center, research is organized into six programs: (1) Molecular Oncology, (2) Comparative Oncology, (3) Cancer Therapeutics, (4) Population Sciences and Health Disparities, (5) Prostate Cancer, (6) Biomedical Technology. This competitive renewal for the P30 [Cancer Center Support Grant] proposes support for (1) senior leadership, (2) program leadership, (3) developmental programs, (4) administration, (5) planning and evaluation activities, (6) nine shared resources including genomics, optical biology, mouse biology, the clinical trials support unit, biostatistics, clinical and molecular pharmacology, animal imaging, biospecimen repository and combinatorial chemistry, (7) the Protocol Review and Monitoring System, (8) protocol-specific research, and (9) Data Safety and Monitoring.
The proposed Cancer Center Support Grant provides the infrastructure for the cancer research enterprise at UC Davis and for center members at other institutions. This infrastructure promotes collaboration and and scientific excellence in cancer research and the application of research to the care of patients benefiting from research at UC Davis and through dissemination, patients everywhere.
|Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331|
|Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182|
|Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529|
|Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162|
|Tepper, Clifford G; Dang, Julie H T; Stewart, Susan L et al. (2018) High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 124 Suppl 7:1583-1589|
|Jerant, Anthony; Fenton, Joshua J; Kravitz, Richard L et al. (2018) Association of Clinician Denial of Patient Requests With Patient Satisfaction. JAMA Intern Med 178:85-91|
|Kirschbaum, Mark H; Frankel, Paul; Synold, Timothy W et al. (2018) A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol 180:445-448|
|Besprozvannaya, Marina; Dickson, Eamonn; Li, Hao et al. (2018) GRAM domain proteins specialize functionally distinct ER-PM contact sites in human cells. Elife 7:|
|Turner, David C; Kondic, Anna G; Anderson, Keaven M et al. (2018) Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res 24:5841-5849|
|Matsumoto, Collin; Jiang, Yan; Emathinger, Jacqueline et al. (2018) Short Telomeres Induce p53 and Autophagy and Modulate Age-Associated Changes in Cardiac Progenitor Cell Fate. Stem Cells 36:868-880|
Showing the most recent 10 out of 836 publications